PortfoliosLab logoPortfoliosLab logo
EXE vs. TGTX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

EXE vs. TGTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Expand Energy Corp (EXE) and TG Therapeutics, Inc. (TGTX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, EXE achieves a -18.63% return, which is significantly lower than TGTX's 66.12% return.


EXE

1D
1.95%
1M
-6.62%
YTD
-18.63%
6M
-20.38%
1Y
-20.29%
3Y*
6.27%
5Y*
14.81%
10Y*

TGTX

1D
3.06%
1M
16.11%
YTD
66.12%
6M
57.96%
1Y
32.51%
3Y*
21.69%
5Y*
5.57%
10Y*
21.61%
*Multi-year figures are annualized to reflect compound growth (CAGR)

EXE vs. TGTX - Yearly Performance Comparison


2026 (YTD)20252024202320222021
EXE
Expand Energy Corp
-18.63%14.35%33.18%-14.77%62.34%53.16%
TGTX
TG Therapeutics, Inc.
66.12%-0.96%76.23%44.38%-37.74%-63.09%

Correlation

The correlation between EXE and TGTX is -0.01, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

-0.01

Correlation (3Y)
Calculated over the trailing 3-year period

0.04

Correlation (5Y)
Calculated over the trailing 5-year period

0.12

Correlation (All Time)
Calculated using the full available price history since Feb 10, 2021

0.12

The correlation between EXE and TGTX shifts across timeframes, from -0.01 (1 year) to 0.12 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

EXE:

$21.37M

TGTX:

$7.93B

EPS

EXE:

$17.89

TGTX:

$2.87

PE Ratio

EXE:

4.96

TGTX:

17.23

PS Ratio

EXE:

1.14

TGTX:

11.37

PB Ratio

EXE:

0.00

TGTX:

13.59

Total Revenue (TTM)

EXE:

$14.10B

TGTX:

$700.35M

Gross Profit (TTM)

EXE:

$8.89B

TGTX:

$581.54M

EBITDA (TTM)

EXE:

$7.00B

TGTX:

$156.88M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

EXE vs. TGTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EXE
EXE Risk / Return Rank: 1515
Overall Rank
EXE Sharpe Ratio Rank: 1515
Sharpe Ratio Rank
EXE Sortino Ratio Rank: 1616
Sortino Ratio Rank
EXE Omega Ratio Rank: 1717
Omega Ratio Rank
EXE Calmar Ratio Rank: 1616
Calmar Ratio Rank
EXE Martin Ratio Rank: 1212
Martin Ratio Rank

TGTX
TGTX Risk / Return Rank: 6363
Overall Rank
TGTX Sharpe Ratio Rank: 6565
Sharpe Ratio Rank
TGTX Sortino Ratio Rank: 6464
Sortino Ratio Rank
TGTX Omega Ratio Rank: 6363
Omega Ratio Rank
TGTX Calmar Ratio Rank: 6464
Calmar Ratio Rank
TGTX Martin Ratio Rank: 6161
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

EXE vs. TGTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Expand Energy Corp (EXE) and TG Therapeutics, Inc. (TGTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


EXETGTXDifference
Sharpe ratioReturn per unit of total volatility

-1.34

Sortino ratioReturn per unit of downside risk

-2.07

Omega ratioGain probability vs. loss probability

0.91

1.16

-0.25

Calmar ratioReturn relative to maximum drawdown

-0.72

1.00

-1.72

Martin ratioReturn relative to average drawdown

-1.31

1.81

-3.12

EXE vs. TGTX - Sharpe Ratio Comparison

The current EXE Sharpe Ratio is -0.64, which is lower than the TGTX Sharpe Ratio of 0.69. The chart below compares the historical Sharpe Ratios of EXE and TGTX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

EXE vs. TGTX - Drawdown Comparison

The maximum EXE drawdown since its inception was -29.69%, smaller than the maximum TGTX drawdown of -99.52%. Use the drawdown chart below to compare losses from any high point for EXE and TGTX.


Loading charts...

Drawdown Indicators


EXETGTXDifference

Max Drawdown

Largest peak-to-trough decline

-29.69%

-99.52%

+69.83%

Max Drawdown (1Y)

Largest decline over 1 year

-28.32%

-32.66%

+4.34%

Max Drawdown (3Y)

Largest decline over 3 years

-28.32%

-75.42%

+47.10%

Max Drawdown (5Y)

Largest decline over 5 years

-29.69%

-90.75%

+61.06%

Max Drawdown (10Y)

Largest decline over 10 years

-93.19%

Current Drawdown

Current decline from peak

-26.92%

-78.79%

+51.87%

Average Drawdown

Average peak-to-trough decline

-10.98%

-91.43%

+80.45%

Ulcer Index

Depth and duration of drawdowns from previous peaks

15.50%

18.04%

-2.54%

Volatility

EXE vs. TGTX - Volatility Comparison

The current volatility for Expand Energy Corp (EXE) is 7.74%, while TG Therapeutics, Inc. (TGTX) has a volatility of 15.65%. This indicates that EXE experiences smaller price fluctuations and is considered to be less risky than TGTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


EXETGTXDifference

Volatility (1M)

Calculated over the trailing 1-month period

7.74%

15.65%

-7.91%

Volatility (6M)

Calculated over the trailing 6-month period

22.57%

34.28%

-11.71%

Volatility (1Y)

Calculated over the trailing 1-year period

31.76%

47.22%

-15.46%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

35.13%

87.77%

-52.64%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

34.78%

86.88%

-52.10%

Dividends

EXE vs. TGTX - Dividend Comparison

EXE's dividend yield for the trailing twelve months is around 3.59%, while TGTX has not paid dividends to shareholders.


PositionTTM20252024202320222021
EXE
Expand Energy Corp
3.59%2.89%2.45%4.70%10.16%1.74%
TGTX
TG Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%

Financials

EXE vs. TGTX - Financials Comparison

This section allows you to compare key financial metrics between Expand Energy Corp and TG Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.001.00B2.00B3.00B4.00B20222023202420252026
4.40B
204.92M
(EXE) Total Revenue
(TGTX) Total Revenue
Values in USD except per share items

EXE vs. TGTX - Profitability Comparison

The chart below illustrates the profitability comparison between Expand Energy Corp and TG Therapeutics, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-50.0%0.0%50.0%100.0%20222023202420252026
84.3%
83.7%
Portfolio components
EXE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Expand Energy Corp reported a gross profit of 3.71B and revenue of 4.40B. Therefore, the gross margin over that period was 84.3%.

TGTX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, TG Therapeutics, Inc. reported a gross profit of 171.41M and revenue of 204.92M. Therefore, the gross margin over that period was 83.7%.

EXE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Expand Energy Corp reported an operating income of 1.53B and revenue of 4.40B, resulting in an operating margin of 34.8%.

TGTX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, TG Therapeutics, Inc. reported an operating income of 34.80M and revenue of 204.92M, resulting in an operating margin of 17.0%.

EXE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Expand Energy Corp reported a net income of 1.16B and revenue of 4.40B, resulting in a net margin of 26.4%.

TGTX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, TG Therapeutics, Inc. reported a net income of 19.78M and revenue of 204.92M, resulting in a net margin of 9.7%.


Frequently Asked Questions


EXE and TGTX have a correlation of -0.01, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

TGTX has higher volatility (15.65%) compared to EXE (7.74%). In terms of maximum drawdown, EXE dropped -29.69% vs TGTX's -99.52%.

TGTX currently has the higher Sharpe Ratio (0.69 vs -0.64), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for EXE and TGTX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer